Skip to main content
. Author manuscript; available in PMC: 2014 Sep 23.
Published in final edited form as: J Allergy Clin Immunol. 2013 Jul 16;132(5):1086–1096.e5. doi: 10.1016/j.jaci.2013.05.020

FIG 4.

FIG 4

Bone marrow eosinophil and neutrophils (%) for individual subjects (ATP population). Only subjects who consented to bone marrow aspiration and provided evaluable samples at screening and endpoint are included.

a) Eosinophils. Cohort 1 IV: placebo n = 1, square with dashed line; benralizumab 1 mg/kg n = 4, diamond with solid line. Cohort 2 SC: benralizumab 100 mg n = 1, circle with solid line.

b) Neutrophils and bands. Cohort 1 IV: placebo, n = 1; benralizumab 1 mg/kg, n = 4. Cohort 2 SC: benralizumab 100 mg n = 1.